This week in drug discovery (28 April – 2 May)
News round-up for 28 April – 2 May by DDW Senior Digital Content Editor Diana Spencer.
With the American Association of Cancer Research (AACR) Annual Meeting taking place from 25-30 April, the DDW news desk has been inundated with the latest advances in cancer drug discovery, so here are a few highlights. Check out our round-up for the event for more updates.
The top stories:
Study advances genetic understanding of testicular cancer
The largest study to date of the most common form of testicular cancer has uncovered a possible link between disease risk and variations in the genes controlling cell shape and movement.
CHMP issues positive opinion for biliary tract cancer treatment
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the conditional marketing authorisation of the EU’s first HER2-targeted therapy for biliary tract cancer (BTC).
New $15 million cancer research grant launched at AACR
The AACR Trailblazer Cancer Research Grant Program, which was launched at the Annual Meeting Opening Ceremony, will award $15 million over three years.
First precision T-cell engager for solid tumours enters the clinic
Clasp Therapeutics has announced the dosing of the initial patient in the GUARDIAN-101 Phase I trial of CLSP-1025, the first tumour-specific TCE to enter clinical development.
NHS England rolls out injectable immunotherapy for 15 cancers
NHS England has become the first national health service in Europe to offer Bristol Myers Squibb’s injectable cancer immunotherapy nivolumab (Opdivo).